Summary
Background Rising rates of suicide, the most dreadful consequence of mental health effects elicited by the coronavirus pandemic (COVID-19) are cause for grave concern. However, the exact association between mental health problems and suicide remains largely unknown in relation to COVID-19.
Methods To determine the impact of COVID-19 on suicide trajectory, we used an interrupted time-series design to analyze monthly suicides rates extracted from Japan’s national database. We next used mixed-effects regression models to investigate the relationship between the nationwide suicide increase in August 2020 and psychiatric states of 4,348 individuals from an online survey performed immediately before (December 2019) and during (August 2020) the pandemic. Psychiatric states included depression, anxiety, and COVID-19-related PTSD, a form of severe event-related stress.
Findings In Japan, suicides had gradually decreased before COVID-19 (β = −0·7×10−3, t57 = −14·2, p = 8·6×10−46), but increased drastically after a state of emergency was declared in April 2020 (β = 0·9×10−2, t57 = 17·3, p = 2·3×10−67). We found that PTSD symptoms reliably predict COVID-19’s impact on suicide rates (β = 6·3×10−4, t3936 = 5·96, p = 2·7×10−9). In contrast, depression scores are a reliable indicator of stress vulnerability (i.e. future suicide increases, β = 0·001, t3936 = 6·6, p = 4·5×10−11). Simulations revealed that a one-point reduction in PTSD score could decrease suicides by up to 3·1 per ten million people per month in Japan.
Interpretation PTSD symptoms may help to identify high-risk groups so as to increase efficacy of prevention policies.
Funding KDDI collaborative research contract, the Innovative Science and Technology Initiative for Security (JPJ004596), ATLA and AMED (JP20dm0307008).
Evidence before this study We searched PubMed on December 2, 2020, for “COVID” and “suicid*” in the titles or abstracts of published articles and obtained 269 hits. No language restrictions were applied to the search. Nearly all previous articles on suicide and COVID-19 have reported simulation studies of suicide counts and rates in case studies, editorials, letters, and commentaries. To date, no study has analyzed the association between psychiatric states and suicide increases in the context of the COVID-19 pandemic.
Added value of this study To the best of our knowledge, this is the first study reporting a concrete approach to predict suicide rate increases from psychiatric states during the COVID-19 pandemic. Our findings indicate that PTSD symptoms are a reliable surrogate endpoint of pandemic-related suicide increase.
Implications of all available evidence This work provides a new perspective on preparing guidelines for suicide prevention. Efforts should focus on reducing PTSD severity for single individuals and populations to reduce the overall suicide risk.
Competing Interest Statement
This study was funded by KDDI Corporation. There is nothing else to disclose.
Funding Statement
KDDI collaborative research contract,the Innovative Science and Technology Initiative for Security (JPJ004596), ATLA and AMED (JP20dm0307008).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We sent participants e-mails contained information about informed consent and completion of the entire questionnaire was considered to indicate a participant's consent. This work is part of a larger study on problematic smartphone use, which was approved by the Ethics Committee of the Advanced Telecommunications Research Institute International (Japan).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The main summary statistics data that support the findings of this study are available within Supplementary Data. Owing to company cohort data sharing restrictions, individual-level data cannot be publicly posted. Data are however available from the authors upon reasonable request and with permission of KDDI Corporation.
